Friday, July 15, 2022

Opinion Today: Could psychedelics cure your depression — without a mind-bending trip?

Scientists are working to capture the benefits without the hallucinations.
Author Headshot

By Alexandra Sifferlin

Senior Staff Editor, Opinion

Psychedelics have long been viewed as providing a potential breakthrough in addressing depression and PTSD, especially for people who do not respond to other treatments, such as certain antidepressant medications that are often prescribed.

Those who have taken psychedelics in clinical trials describe the hallucinations that accompany the drugs as transformative. "It forced me to reconcile with the mortality of being human," one study subject shared. "It alleviated my anxiety and gave meaning to my life."

Despite these dispatches, as the health writer Dana Smith reports for Times Opinion, some scientists want to turn what's currently a mind-bending experience into a banal one. They are working to develop molecules based on psychedelics that provide the psychological benefits of the drugs without the hallucinations.

The reasons largely have to do with scale. There are concerns that psychedelic therapy for depression and PTSD will not be easily accessible if it is approved for use in its current form. People may not want to trip or may find the treatment overwhelming. They also have to use the drugs in a clinic under supervision. If the same effects could be gained by taking a pill in the morning, scientists reason, millions more people might be able to benefit.

Other researchers are skeptical that people can be healed without a trip. "To them, the powerful emotional and mystical experiences caused by psychedelics are what lead to people's therapeutic breakthroughs," Smith writes.

The good news is that, regardless of the drugs' form, the results of trials suggest that they have the potential to change the way depression is treated going forward. "That's because the truly revolutionary vision of both psychedelic therapy and its non-psychedelic chemical cousins is to take the medications not on a daily or weekly basis, but only once or twice and potentially be healed for good," she writes.

As one expert asked her: "Wouldn't it be wonderful if we had a drug that you can take at bedtime and you woke up the next day and you were no longer depressed?"

It certainly would.

ADVERTISEMENT

Here's what we're focusing on today:

On the News

Thomas L. Friedman

Only Saudi Arabia and Israeli Arabs Can Save Israel as a Jewish Democracy

An existential question continues to haunt Israel.

By Thomas L. Friedman

Article Image

Michelle Goldberg

A 10-Year-Old Endures the Predictable Result of an Abortion Ban

Why is the right in denial about what their laws do?

By Michelle Goldberg

Article Image

Paul Krugman

Why Markets Shrugged Off Bad Inflation News

An ugly report may not be the shape of things to come.

By Paul Krugman

Article Image

Jamelle Bouie

Republicans Are Already Threatening the Right to Travel

Dobbs has them all fired up.

By Jamelle Bouie

Article Image

Guest Essay

It's Terrifying to Be a Doctor in Post-Roe America

A colleague's terrifying ordeal shows that physicians are at risk just for doing their jobs.

By Tracey A. Wilkinson

Article Image

Farhad Manjoo

The Webb Telescope Restored (Some of) My Faith in Humanity

The machine that's a low-key triumph of the human spirit.

By Farhad Manjoo

Article Image

ADVERTISEMENT

ADVERTISEMENT

Subscribe Today

New York Times Opinion curates a wide range of views, inviting rich discussion and debate that helps readers analyze the world. This work is made possible with the support of subscribers. Please consider subscribing to The Times with this special offer.

Games Here is today's Mini Crossword and Spelling Bee. If you're in the mood to play more, find all our games here.

Forward this newsletter to friends to share ideas and perspectives that will help inform their lives. They can sign up here. Do you have feedback? Email us at opiniontoday@nytimes.com.

Contact us if you have questions about your Times account, delivery problems or other issues, visit our Help Page or contact The Times.

Need help? Review our newsletter help page or contact us for assistance.

You received this email because you signed up for the Opinion Today newsletter from The New York Times.

To stop receiving these emails, unsubscribe or manage your email preferences.

Subscribe to The Times

Connect with us on:

facebooktwitterinstagram

Change Your EmailPrivacy PolicyContact UsCalifornia Notices

LiveIntent LogoAdChoices Logo

The New York Times Company. 620 Eighth Avenue New York, NY 10018

No comments:

Post a Comment